Sequence Analysis of Pvama-1 among
Genetic variation
Iran
Plasmodium vivax
PvAMA-1
Sistan
Journal
Ethiopian journal of health sciences
ISSN: 2413-7170
Titre abrégé: Ethiop J Health Sci
Pays: Ethiopia
ID NLM: 101224773
Informations de publication
Date de publication:
01 Jul 2020
01 Jul 2020
Historique:
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
30
7
2021
Statut:
ppublish
Résumé
Apical Membrane antigen 1 (AMA-1) is an important membrane protein that presents in all Plasmodium species and participates in critical phases in the attraction of cells. In human, it is one of the most immunodominant antigens with a protective immune response simulation role Apical Membrane antigen 1 (AMA-1) is an important membrane protein which presents in all Plasmodium species and is located on the surface of merozoite and sporozoites that participates in critical phases in attraction of human red blood cells by merozoites and hepatocytes by sporozoites, so in human, it is one of the most immunodominant antigens with a protective immune response simulation role. Since extra information is necessary to lighten of AMA-1 scope, we equaled genetic variation in P.vivax AMA-1 from 40 Iranian isolates with those reported from the other malarious countries. Blood samples were collected from 40 patients' positive of P.vivax, and genomic DNA was extracted from the blood. The nucleotide sequence for 446 amino acid (AA) residues (42-488 of PvAMA-1) of AMA-1 gene was amplified via PCR and then sequenced. A total of 24 different haplotypes were recognized between samples. No new haplotype was determined in this research that was reported previously in other regions of Iran and the world. We detected 37-point mutations at the nucleotide level in their sequences and showed 43 amino acid variations, at 37 positions in which 6 sites demonstrate trimorphic polymorphism, and the others were dimorphic. Sequence analysis of the major haplotype showed 95% similarity with P.vivax Sal-1 AMA-1 gene and high level of allelic diversity at the domain I of PvAMA-1 among
Sections du résumé
BACKGROUND
BACKGROUND
Apical Membrane antigen 1 (AMA-1) is an important membrane protein that presents in all Plasmodium species and participates in critical phases in the attraction of cells. In human, it is one of the most immunodominant antigens with a protective immune response simulation role Apical Membrane antigen 1 (AMA-1) is an important membrane protein which presents in all Plasmodium species and is located on the surface of merozoite and sporozoites that participates in critical phases in attraction of human red blood cells by merozoites and hepatocytes by sporozoites, so in human, it is one of the most immunodominant antigens with a protective immune response simulation role. Since extra information is necessary to lighten of AMA-1 scope, we equaled genetic variation in P.vivax AMA-1 from 40 Iranian isolates with those reported from the other malarious countries.
METHODS
METHODS
Blood samples were collected from 40 patients' positive of P.vivax, and genomic DNA was extracted from the blood. The nucleotide sequence for 446 amino acid (AA) residues (42-488 of PvAMA-1) of AMA-1 gene was amplified via PCR and then sequenced.
RESULT
RESULTS
A total of 24 different haplotypes were recognized between samples. No new haplotype was determined in this research that was reported previously in other regions of Iran and the world. We detected 37-point mutations at the nucleotide level in their sequences and showed 43 amino acid variations, at 37 positions in which 6 sites demonstrate trimorphic polymorphism, and the others were dimorphic.
CONCLUSION
CONCLUSIONS
Sequence analysis of the major haplotype showed 95% similarity with P.vivax Sal-1 AMA-1 gene and high level of allelic diversity at the domain I of PvAMA-1 among
Identifiants
pubmed: 33897211
doi: 10.4314/ejhs.v30i4.6
pmc: PMC8054451
doi:
Substances chimiques
Antigens, Protozoan
0
Protozoan Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
513-520Informations de copyright
Copyright: © 2020 Hadi M., et al.
Références
Exp Parasitol. 2007 Jul;116(3):252-6
pubmed: 17336299
Vet World. 2017 Aug;10(8):854-858
pubmed: 28919673
J Mol Biol. 2005 Jul 22;350(4):641-56
pubmed: 15964019
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5552-7
pubmed: 15805191
PLoS Pathog. 2009 Mar;5(3):e1000322
pubmed: 19283086
Iran J Parasitol. 2015 Apr-Jun;10(2):197-205
pubmed: 26246817
Int J Parasitol. 2005 Feb;35(2):185-92
pubmed: 15710439
Infect Immun. 2000 Dec;68(12):7078-86
pubmed: 11083833
Iran J Parasitol. 2012;7(1):26-31
pubmed: 23133468
Vaccine. 2011 Oct 6;29(43):7491-504
pubmed: 21784116
Infect Genet Evol. 2013 Dec;20:239-48
pubmed: 24044894
Infect Genet Evol. 2019 Jul;71:224-231
pubmed: 30953716
Malar J. 2010 Jun 21;9:175
pubmed: 20565971
Nat Genet. 2012 Sep;44(9):1046-50
pubmed: 22863733
Ethiop J Health Sci. 2019 Sep;29(5):613-622
pubmed: 31666783
Infect Immun. 2013 May;81(5):1491-501
pubmed: 23429537
J Microbiol Methods. 2016 Apr;123:44-50
pubmed: 26851675
Mol Microbiol. 2000 Nov;38(4):706-18
pubmed: 11115107
Hum Vaccin. 2010 Jan;6(1):124-32
pubmed: 20009526
Malar J. 2015 Nov 16;14:455
pubmed: 26572984
Int J Mol Cell Med. 2017 Fall;6(4):222-234
pubmed: 29988191
N Engl J Med. 2011 Sep 15;365(11):1004-13
pubmed: 21916638
J Mol Biol. 2007 Mar 9;366(5):1523-37
pubmed: 17229439
Hum Vaccin. 2010 Jan;6(1):39-53
pubmed: 20061790
Trends Parasitol. 2008 Feb;24(2):74-84
pubmed: 18226584
Malar J. 2012 Nov 26;11:391
pubmed: 23181845
Exp Parasitol. 2012 Apr;130(4):456-62
pubmed: 22306282
PLoS Pathog. 2013;9(12):e1003840
pubmed: 24385910
Lancet. 2005 Dec 3;366(9501):1908-9
pubmed: 16325683
Lancet. 2012 Aug 11;380(9841):559-60
pubmed: 22883497
Iran J Parasitol. 2012;7(2):8-14
pubmed: 23109940